Sonidegib in Adult Patients With Locally Advanced Basal Cell Carcinoma (laBCC) in China

NCT06880848 | Completed Phase 4

• 1 other identifier: AM20220301
• Study Type: interventional
• Target: 160
• Locations: 1 country
• Sites: 1

Brief Summary

This is a Phase IV, single arm, multicenter study designed to evaluate the efficacy and safety profile of Sonidegib in chinese participants with locally advanced basal cell carcinoma (laBCC) who are not amenable to radiation therapy, curative surgery or other local therapies.

Conditions

Carcinoma, Basal Cell (BCC)

Keywords

BCC; Basal Cell Carcinoma

Outcome Measures

Primary Outcomes (1)

• Objective Response Rate (ORR)

  Objective response rate (ORR) is defined as the percentage of participants with a confirmed complete or partial response (CR or PR) , per modified Response Evaluation Criteria in Solid Tumors (mRECIST) as assessed by central review.

  up to 1 year

Secondary Outcomes (5)

• Duration of Response (DoR)

  up to 1 year

• Complete response rate (CRR) per central and investigator review

  up to 1 year

• Progression-free Survival (PFS)

  up to 1 year

• Time to tumor response (TTR)

  up to 1 year

• Adverse event (AE)/Serious adverse event (SAE)/Treatment emergent adverse event (TEAE)

  up to 1 year

Study Arms (1)

Sonidegib Phosphate Capsules

EXPERIMENTAL

Participants will receive continuous treatment with oral administration once a day until conditions for treatment termination are met.

Drug: Sonidegib Phosphate Capsules

Interventions

Sonidegib Phosphate Capsules DRUG

Sonidegib should be taken 1 hour before or 2 hours after a breakfast

Sonidegib Phosphate Capsules

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 18 years or older.
• Patients with a histologically confirmed diagnosis of laBCC that is not amenable to radiation therapy, curative surgery, or other local therapies. Patients with laBCC must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as ≥ 10 mm, with MRI/CT scan or on color photographs.
• ECOG PS Score ≤ 2.
• Patients with adequate bone marrow, liver and renal function.
• Written informed consent obtained prior to any screening procedures.
• Patients are willing and able to comply with the scheduled visits, treatment plan, laboratory testing, study procedures, and restrictions.
• Females of childbearing potential agree to use contraception during treatment and for 20 months following the last dose; male patients (even after vasectomy) agree to use contraception during treatment and for 8 months after the last dose.

You may not qualify if:

• Subjects in the opinion of the investigator are immunosuppressed (e.g., organ transplant recipients, HIV, systemic invasive malignancy within past 5 years excluding Stage I cervical cancer, ductal carcinoma in situ of the breast or CLL stage 0, graft vs. host disease, etc.).
• LaBCC patients with skin lesions in multiple body locations will not be considered metastatic patients. LaBCC patients with positive (histological confirmation of BCC) regional nodal disease will be considered to have metastatic disease.
• Poorly controlled diabetes mellitus (as per Investigator's discretion in consultation with Sponsor's medical monitor).
• Major surgery within 4 weeks prior to study treatment.
• Patients with concurrent uncontrolled medical conditions that may interfere with their participation in the study or potentially affect the interpretation of the study data.
• Patients unable to take oral drugs or with lack of physical integrity of the upper gastrointestinal tract or known malabsorption syndromes.
• Patients who have previously been treated with systemic Sonidegib or with other Hh pathway inhibitors.
• Patients who have neuromuscular disorders (e.g. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy).
• Patients who are planning on embarking on a new strenuous exercise regimen after initiation of study treatment.
• Have participated in other clinical trials within 4 weeks prior to the first dose of sonidegib.
• Have received other anti-neoplastic therapy within 4 weeks prior to study treatment.
• Patients who are receiving medications known to be moderate and strong inhibitors or inducers of cytochrome P450 (CYP) 3A4/5 or drugs metabolized by CYP2B6 or CYP2C9 that have narrow therapeutic index, and that cannot be discontinued before starting treatment with sonidegib. Medications that are strong CYP3A4/5 inhibitors should be discontinued at least 7 days and strong CYP3A/5 inducers for at least 2 weeks prior to starting treatment with sonidegib.
• Pregnant or nursing (lactating) women, confirmed by a positive hCG laboratory test (\> 5mIU/mL).
• Unwilling or unable to comply with the protocol.

Sponsors & Collaborators

• Jemincare: lead
• Sun Pharmaceutical Industries Limited: collaborator
• Zhejiang Hangyu Pharmaceutical Co., Ltd.: collaborator

Study Sites (1)

Peking University First Hospital

Beijing, China, 100034, China

Location

MeSH Terms

Conditions

Carcinoma; Carcinoma, Basal Cell

Condition Hierarchy (Ancestors)

Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Basal Cell

Study Officials

• Hang Li

  Peking University First Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 12, 2025
• First Posted: March 18, 2025
• Study Start: June 21, 2023
• Primary Completion: August 26, 2025
• Study Completion: August 26, 2025
• Last Updated: September 24, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)